A new Beginning..., page-3396

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 3396 Last

Share
Profile

Follow
Siva108

8,834 Posts.

584

18/11/19

13:28

Post #: 41484407
Share

Originally posted by pilko3: ↑

here we go again...the company is sold done and dusted for anywhere from $1.50 to $30 per share and we don't have TGA adult FDA for only 3 conditions and sleep apnea diagnostic hasn't been lodged for CE yet. It is fun to boggle the brain with delusions of a grand takeover but lets put a sock in it for awhile so we can keep perspective. I
agree with AICp that the big unloader isn't done yet...sort of a good thing as if they are dumping 10 million plus shares then the new holders will be more likely to hold out for a bigger T/O figure if an offer ever comes if RAP ever get the approvals and acceptance they need. IF, IF, IF...
But...if ResMed are going to do 100 million test per year for the next 6 years they will need ResAp one would think...mad if they didn't use it as an economical and speedy pathway to getting the 1 afflicted client from 4 tests they claim to get. $35 per test ($20 m up front for the licence...94 m bonus shares) by a million test p.a. and Yo! Right there is $3.5 billion p.a. in revenue. Plus another $1 billion p.a. from cough tests (250,000 per week per year at $10) sees RAP earning $4.5 billion per year That may get a buyout figure of around $6 per share. Nice! The buyout range should be, if ever there was one on the cards, between AUD $4 and AUD $6 IMHO. Aggrh...see you guys sucked me into the buyout figure speculation game...again. We should try and stay frosty the company is what it is...we wait for now and chew what is left of our fingernails. I reckon the 960 shareholders that are not in the top 20 hold the sway re voting power...stay solid!

Expand

You don’t know if CE has or has not been lodged for Sleep Apnea. Management never informed the market they had lodged TGA for children for ResappDx - they only announced the approval...

RAP Price at posting: 27.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 53 more messages in this thread...

First 3396 Last

Add RAP (ASX) to my watchlist

A new Beginning..., page-3396

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Featured News